Capricor Therapeutics posted a net loss of $24.6 million in Q3 2025 with no reported revenue, while operating expenses rose sharply year-over-year. The company ended the quarter with $98.6 million in cash, projecting sufficient funds through Q4 2026.
Revenue fell to $0 in Q3 2025, compared to $2.26 million in Q3 2024.
Net loss widened to $24.6 million, or $0.54 per share.
Total operating expenses increased to $26.3 million, driven by higher R&D spend.
Cash and equivalents were $98.6 million as of quarter-end, expected to last through Q4 2026.
Capricor expects its current cash position to fund operations into Q4 2026, excluding potential milestone payments or additional capital use.
Analyze how earnings announcements historically affect stock price performance